A Director at FibroGen is Exercising Options


Yesterday it was reported that a Director at FibroGen (NASDAQ: FGEN), Toshinari Tamura, exercised options to sell 12,000 FGEN shares at $19.05 a share, for a total transaction value of $727.8K.

Following Toshinari Tamura’s last FGEN Sell transaction on March 15, 2018, the stock climbed by 8.4%.

See today’s analyst top recommended stocks >>

Based on FibroGen’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $43.95 million and GAAP net loss of $23.42 million. In comparison, last year the company earned revenue of $29 million and had a GAAP net loss of $33.18 million. Currently, FibroGen has an average volume of 308.5K. The Company has a Price to Book ratio of 10.1166.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts